$17.02 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Pharvaris

Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.

Stock Analysis

last close $17.02
1-mo return -27.3%
3-mo return 4.1%
avg daily vol. 4.81T
52-week high 27.5
52-week low 13.14
market cap. $630M
forward pe -
annual div. -
roe -25.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 76.1%

Subscribe now for daily local and international financial news